MIT Researchers Develop AI Method for Thermostable mRNA Vaccines
A novel AI-guided technique enables mRNA vaccines to remain stable at higher temperatures, potentially revolutionizing vaccine storage and distribution.
MIT's new method stabilizes mRNA vaccines at 37°C for over two months.
Thermostable formulations could reduce storage costs by up to 86%.
The approach allows for vaccine delivery via microneedle patches, eliminating the need for injections.
Researchers at MIT have made significant strides in the development of mRNA vaccines by creating a method that allows these vaccines to remain stable at elevated temperatures. This breakthrough, reported in Nature Biotechnology, could drastically reduce the reliance on cold storage, which has been a major logistical challenge in vaccine distribution. The new formulation retains full bioactivity after being stored at 37°C (98.6°F) for over two months and can remain stable at room temperature for up to a year.
Historically, mRNA vaccines have required refrigeration or freezing to maintain their efficacy, which complicates distribution, especially in regions with limited resources. The new thermostable formulations could address these issues by significantly lowering storage costs and improving accessibility. Previous estimates suggest that such vaccines could reduce storage expenses by 71% to 86% and cut wastage costs by at least 50%, making them more economically viable.
The researchers utilized an innovative approach called Algorithm-Guided Experimental design for lipid Nanoparticle Thermostabilization (AGENT). This AI-driven method allowed them to identify optimal combinations of excipients—ingredients that help protect the lipid nanoparticles (LNPs) during storage. Starting with nearly 50 FDA-approved excipients, AGENT streamlined the formulation process, completing optimization in just six iterations over a month, a significant reduction from the usual lengthy trial-and-error methods.
The implications of this research extend beyond cost savings. The ability to deliver mRNA vaccines through dissolvable microneedle patches could revolutionize vaccination methods, making them less invasive and more user-friendly. In preclinical studies with rodents and nonhuman primates, the thermostable formulations elicited immune responses comparable to those of freshly prepared injectable vaccines, demonstrating their potential effectiveness.
While the findings are promising, further research is necessary to ensure manufacturing consistency and regulatory compliance. The researchers noted structural changes in the LNPs during reconstitution, indicating that standardized methods will be crucial for assessing product quality. Nonetheless, this AI-guided approach to formulation could pave the way for broader applications of mRNA vaccines and therapeutics, addressing a significant barrier to their widespread use.
